Drug Trial Radar · NCT06438978
Tuberculosis Vaccine in Healthy Indian Adults
Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jan 19, 2024
Primary completion
Jan 29, 2024
Study completion Jul 27, 2024
Sponsor
- Lead sponsor
- Bharat Biotech International LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An Open-labelled, Phase I Clinical Trial to Assess the Safety, Reactogenicity, Tolerability, and Immunogenicity of MTBVAC in healthy Indian adult volunteers A total of 30 subjects with Quantiferon®-TB Gold Plus assay negative and ages 18 to 65 years will be enrolled in this trial. All the subjects will receive a single dose of MTBVAC via the intradermal route in the right deltoid region. DSMB meetings will be conducted after Day 28 , Day 90 \& Day 180 after vaccinating all subjects.
Conditions
- Tuberculosis
Interventions
Tuberculosis VaccineBiological
1. Live, attenuated Mycobacterium tuberculosis (M. tb)- MTBVAC (MTBVAC)01 strain 2. 3-17x105CFU (Per dose) Sucrose Sodium glutamate 3. Lyophilized pellet in vials (10doses) 4. 0.1 mL/dose (After reconstitution with 1 mL/vial sterilized water for injection)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and reactogenicity of MTBVAC Immediate reactionTime frame: 30 Minutes of vaccination.
- To evaluate the safety and reactogenicity of MTBVAC-Solicited adverse eventsTime frame: 14 days
- To evaluate the safety and reactogenicity of MTBVAC-injection site reactionsTime frame: 90 Days
- To evaluate the safety and reactogenicity of MTBVAC-unsolicited adverse eventsTime frame: Through out the trial duration till Day180 Days
- To evaluate the safety and reactogenicity of MTBVAC-Serious Adverse Events (SAEs)Time frame: Through out the trial duration till Day180 Days
- To evaluate the safety and reactogenicity of MTBVAC-AESI (Adverse Event of Special Interest)Time frame: Through out the trial period till Day180 Days
- To evaluate the safety and reactogenicity of MTBVAC-Hematological safety test levels before and after vaccinationTime frame: before and after vaccination on Day 0
- To evaluate the safety and reactogenicity of MTBVAC-Biochemical safety test levels before and after vaccinationTime frame: before and after vaccination on Day 0
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NIMS, Hyderabad
Hyderabad, Telangana, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.